nivolumab,Ipilimumab,cabozantinib
bms
['rcc,(-irccs),(-srcc),(-urcc)']
reports of the can-i trial - first triplet trial in non-clear cell rcc #asco23 
Oncologist, physician-scientist, Assistant Professor @YaleCancer @YaleMed | cancer immunotherapy, genomics, kidney cancer | tweets ≠ medical advice.